Advertisement
CDT vs CMND
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDT is a Buy and CMND is a Buy.
CDT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 17, 2026
CDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 39 cases where CDT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CDT entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.001) is normal, around the industry mean (2.978). P/E Ratio (-0.000) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CMND's RSI Indicator ascending out of oversold territory
The RSI Oscillator for CMND moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 40 similar instances when the indicator left oversold territory. In 36 of the 40 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CMND just turned positive on September 28, 2026. Looking at past instances where CMND's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMND advanced for three days, in 105 of 131 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CMND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 34 cases where CMND's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMND as a result. In 97 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CMND entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CMND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.594) is normal, around the industry mean (2.978). P/E Ratio (-0.106) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMND’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| CDT | CMND | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | N/A | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | N/A | 5 days ago 80% |
| Declines ODDS (%) | 6 days ago 90% | 8 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CDT’s FA Score shows that 1 FA rating(s) are green while CMND’s FA Score has 0 green FA rating(s).
- CDT’s FA Score: 1 green, 4 red.
- CMND’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CDT’s TA Score shows that 1 TA indicator(s) are bullish while CMND’s TA Score has 4 bullish TA indicator(s).
- CDT’s TA Score: 1 bullish, 2 bearish.
- CMND’s TA Score: 4 bullish, 4 bearish.
Price Growth
CDT (@Biotechnology) experienced а -64.67% price change this week, while CMND (@Biotechnology) price change was -1.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CDT has been loosely correlated with SLXN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CDT jumps, then SLXN could also see price increases.
| Ticker / NAME | Correlation To CDT | 1D Price Change % | ||
|---|---|---|---|---|
| CDT | 100% | -14.52% | ||
| SLXN - CDT | 44% Loosely correlated | +0.52% | ||
| PEPG - CDT | 34% Loosely correlated | +6.30% | ||
| CMND - CDT | 32% Poorly correlated | +2.85% | ||
| NRXP - CDT | 27% Poorly correlated | -0.38% | ||
| LTRN - CDT | 25% Poorly correlated | +2.35% | ||
More | ||||
CMND and
Correlation & Price change
A.I.dvisor indicates that over the last year, CMND has been loosely correlated with HURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMND jumps, then HURA could also see price increases.
| Ticker / NAME | Correlation To CMND | 1D Price Change % | ||
|---|---|---|---|---|
| CMND | 100% | +2.85% | ||
| HURA - CMND | 37% Loosely correlated | -1.12% | ||
| CDT - CMND | 32% Poorly correlated | -14.52% | ||
| DRUG - CMND | 31% Poorly correlated | +2.56% | ||
| ENVB - CMND | 31% Poorly correlated | +3.60% | ||
| SLGL - CMND | 27% Poorly correlated | +1.28% | ||
More | ||||